inbnt10q_20091116.htm
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
12b-25
Commission
File Number 001-31668
NOTIFICATION
OF LATE FILING
| (Check
One): |
o Form
10-K |
o Form
11-K |
o Form
20-F |
x Form
10-Q |
o Form
N-SAR |
For
Period Ending: September 30,
2009
o Transition
Report on Form 10-K o Transition Report on
Form 10-Q
o Transition
Report on Form 20-F o
Transition Report on Form N-SAR
o Transition
Report on Form 11-K
Read
the attached instruction sheet before preparing form. Please print or
type.
Nothing
in this form shall be construed to imply that the Commission has verified any
information contained herein.
If the
notification relates to a portion of the filing checked above, identify the
Item(s) to which the notification relates:
Part
I. Registrant Information
Full name
of registrant: Integrated BioPharma,
Inc.
Former
name if applicable:
Address
of principal executive office (Street and number): 225 Long
Avenue
City,
State and Zip Code: Hillside, New Jersey
07205
Part
II. Rule 12b-25(b) and (c)
If the
subject report could not be filed without unreasonable effort or expense and the
registrant seeks relief pursuant to Rule 12b-25(b), the following should be
completed. (Check appropriate box.)
x (a) The reasons
described in reasonable detail in Part III of this form could not be eliminated
without unreasonable effort or expense;
x (b) The subject annual
report, semi-annual report, transition report on Form 10-K, 20-F, 11-K or Form
N-SAR, or portion thereof will be filed on or before the 15th calendar day
following the prescribed due date; or the subject quarterly report on transition
report on Form 10-Q, or portion thereof will be filed on or before the fifth
calendar day following the prescribed due date; and
x (c) The
accountant's statement or other exhibit required by Rule 12b-25(c) has been
attached is applicable.
Part
III. Narrative
State
below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR or
the transition report portion thereof could not be filed within the prescribed
time period. (Attached extra sheets if needed.)
The Company's Quarterly Report on Form 10-Q for the
fiscal period ended September 30, 2009 cannot be filed within the prescribed
time period because the Company is experiencing delays in the collection and
compilation of certain information required to be included in the Form 10-Q. The
Company's Quarterly Report on Form 10-Q will be filed on or before the fifth
calendar day following the prescribed due date.
Part
IV. Other Information
(1) Name
and telephone number of person to contact in regard to this
notification
| Louis
Goldberg |
(212) |
592-1498 |
| (Name) |
(Area
Code) |
(Telephone
Number) |
(2) Have
all other periodic reports required under Section 13 or 15(d) of the Securities
Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during
the preceding 12 months or for such shorter period that the registrant was
required to file such report(s) been filed? If the answer is no, identify
report(s). x Yes o
No
(3) Is it
anticipated that any significant change in results of operations from the
corresponding period for the last fiscal year will be reflected by the earnings
statements to be included in the subject report or portion thereof? o Yes x| No
If so,
attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.
INTEGRATED BIOPHARMA,
INC.
(Name of
registrant as specified in charter)
has
caused this notification to be signed on its behalf by the undersigned thereunto
duly authorized.
| Date November 16,
2009 |
By /s/ Dina L.
Masi |
| |
Name: Dina L.
Masi |
| |
Title: Chief
Financial Officer & Senior Vice
President
|